Safety and efficacy of an rAd26 and   rAd5 vector-based heterologous prime-boost COVID-19 vaccine_ an interim   analysis of a randomised controlled phase 3 trial in Russia

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine_ an interim analysis of a randomised controlled phase 3 trial in Russia

Laisser un commentaire